EU opens antitrust investigation into Vifor Pharma for trashing rival Pharmacosmos

The EU Commission is concerned that Vifor Pharma might have abused a ”dominant position” by spreading false safety information about its closest European competitor on the IV iron treatment market, Pharmacosmos.
Margrethe Vestager, EU Commissioner for Competition | Photo: Jennifer Jacquemart / European Union/European Commission
Margrethe Vestager, EU Commissioner for Competition | Photo: Jennifer Jacquemart / European Union/European Commission
by mikkel aabenhus hemmingsen, translated by daniel pedersen

Monofer, an iron deficiency drug developed by Pharmacosmos, might have faced unfair conditions on the European market for years due to possible disparaging attempts by Vifor Pharma, according to the EU Commission, whose concerns have now led to a formal antitrust investigation into the matter.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading